Volume 152, Issue 8, Pages 1954-1964 (June 2017) Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality  Marina Serper, Tamar H. Taddei, Rajni Mehta, Kathryn D’Addeo, Feng Dai, Ayse Aytaman, Michelle Baytarian, Rena Fox, Kristel Hunt, David S. Goldberg, Adriana Valderrama, David E. Kaplan  Gastroenterology  Volume 152, Issue 8, Pages 1954-1964 (June 2017) DOI: 10.1053/j.gastro.2017.02.040 Copyright © 2017 AGA Institute Terms and Conditions

Figure 1 First HCC-directed therapy received. Percentage of veterans receiving hepatic resection, liver transplantation, ablative therapies (radiofrequency, microwave, or cryo-ablation), trans-arterial therapies (bland, chemo- or radio-embolization), hospice care, and no active therapy as first intervention stratified by BCLC stage. Gastroenterology 2017 152, 1954-1964DOI: (10.1053/j.gastro.2017.02.040) Copyright © 2017 AGA Institute Terms and Conditions

Figure 2 Unadjusted median survival stratified by BCLC stage. Kaplan-Meier survival analysis of 5-year overall survival shown. Gastroenterology 2017 152, 1954-1964DOI: (10.1053/j.gastro.2017.02.040) Copyright © 2017 AGA Institute Terms and Conditions

Figure 3 Correlation between receipt of active HCC therapy and overall survival at the regional level. Spearman correlation of the proportion of patients receiving active HCC therapy (defined as resection, transplantation, ablation, trans-arterial therapy, or sorafenib) (“Proportion treated”) and median overall survival (OS) in months grouped by Veterans Integrated Service Network region. The diameter of each circle is proportional to the number of HCC cases in each Veterans Integrated Service Network. Gastroenterology 2017 152, 1954-1964DOI: (10.1053/j.gastro.2017.02.040) Copyright © 2017 AGA Institute Terms and Conditions

Supplementary Figure 1 Gastroenterology 2017 152, 1954-1964DOI: (10.1053/j.gastro.2017.02.040) Copyright © 2017 AGA Institute Terms and Conditions